MedTrace Logo

Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal Vasculopathy

NCT01248117 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2010-11-25

No results posted yet for this study

Summary

Monthly, continuous anti-vegf therapy for patients presenting with active polypoidal choroidal vasculopathy. Two arms, treatment naive and previously treated with an FDA approved anti-VEGF therapy, will be randomized and dosed with open label 2.0mg ranibizumab.

Conditions

  • Polypoidal Choroidal Vasculopathy

Interventions

DRUG

ranibizumab 2.0mg

Monthly, intravitreal injection 0.05ml

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Retina Consultants of Hawaii

    lead OTHER

Principal Investigators

  • Gregg T Kokame, MD, MMM · Retina Consultants of Hawaii

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
25 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2012-12-31
Completion
2013-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01248117 on ClinicalTrials.gov